Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan monotherapy in advanced PPGL, pNET, VHL-associated tumors, wt GIST, and HIF-2 alpha altered solid tumors
jRCT2011220024Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of belzutifan in pheochromocytoma and paraganglioma (PPGL), islet cell tumor, von Hippel–Lindau disease (VHL) and 2 more, sponsored by Merck & Co. Primary endpoint: Objective response rate. Started Nov 2022; status: recruiting.
02
Drugs
belzutifan
03
Conditions
pheochromocytoma and paraganglioma (PPGL)islet cell tumorvon Hippel–Lindau disease (VHL)gastrointestinal stromal tumor (GIST)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2011220024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220024.